These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 28398342)

  • 21. Trajectories and antecedents of treatment response over time in early-episode psychosis.
    Levine SZ; Rabinowitz J
    Schizophr Bull; 2010 May; 36(3):624-32. PubMed ID: 18849294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spatial working memory and problem solving in schizophrenia: the effect of symptom stabilization with atypical antipsychotic medication.
    Snyder PJ; Jackson CE; Piskulic D; Olver J; Norman T; Maruff P
    Psychiatry Res; 2008 Sep; 160(3):316-26. PubMed ID: 18579217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first-episode psychosis.
    MacDonald AW; Carter CS; Kerns JG; Ursu S; Barch DM; Holmes AJ; Stenger VA; Cohen JD
    Am J Psychiatry; 2005 Mar; 162(3):475-84. PubMed ID: 15741464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lack of association between clinical and cognitive change in first-episode psychosis: the first 6 weeks of treatment.
    González-Blanch C; Crespo-Facorro B; Alvarez-Jiménez M; Rodríguez-Sánchez JM; Pérez-Iglesias R; Pelayo-Terán JM; Martínez-García O; Vázquez-Barquero JL
    Can J Psychiatry; 2008 Dec; 53(12):839-47. PubMed ID: 19087482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of symptomatology and cognitive deficits to functional capacity in schizophrenia.
    Perlick DA; Rosenheck RA; Kaczynski R; Bingham S; Collins J
    Schizophr Res; 2008 Feb; 99(1-3):192-9. PubMed ID: 17851042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of early stable symptomatic remission after an exacerbation of schizophrenia: the significance of symptoms, neuropsychological performance and cognitive biases.
    Andreou C; Roesch-Ely D; Veckenstedt R; Bohn F; Aghotor J; Köther U; Pfueller U; Moritz S
    Psychiatry Res; 2013 Dec; 210(3):729-34. PubMed ID: 23998362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses].
    Chabannes JP; Pelissolo A; Farah S; Gerard D
    Encephale; 1998; 24(4):386-92. PubMed ID: 9809244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
    Akhondzadeh S; Mohammadi N; Noroozian M; Karamghadiri N; Ghoreishi A; Jamshidi AH; Forghani S
    Schizophr Res; 2009 Feb; 107(2-3):206-12. PubMed ID: 18789844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment.
    Snitz BE; MacDonald A; Cohen JD; Cho RY; Becker T; Carter CS
    Am J Psychiatry; 2005 Dec; 162(12):2322-9. PubMed ID: 16330597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
    Ohrmann P; Siegmund A; Suslow T; Pedersen A; Spitzberg K; Kersting A; Rothermundt M; Arolt V; Heindel W; Pfleiderer B
    J Psychiatr Res; 2007 Oct; 41(8):625-34. PubMed ID: 16949099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine.
    Hofer A; Rettenbacher MA; Edlinger M; Huber R; Bodner T; Kemmler G; Sachs G; Fleischhacker WW
    Pharmacopsychiatry; 2007 Jan; 40(1):1-8. PubMed ID: 17327953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychopathological syndromes of schizophrenia: evaluation of the dimensional structure of the positive and negative syndrome scale.
    Mass R; Schoemig T; Hitschfeld K; Wall E; Haasen C
    Schizophr Bull; 2000; 26(1):167-77. PubMed ID: 10755679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of risperidone on cognition in patients with schizophrenia.
    Stip E; Lussier I
    Can J Psychiatry; 1996 Oct; 41(8 Suppl 2):S35-40. PubMed ID: 8899249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Empirical validation of competing definitions of schizophrenia: a poly-diagnostic study of cognitive impairment in non-affective psychosis.
    Cuesta MJ; Peralta V; Zarzuela A
    Schizophr Res; 2007 Sep; 95(1-3):39-47. PubMed ID: 17651943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function.
    Swerdlow NR; Light GA; Cadenhead KS; Sprock J; Hsieh MH; Braff DL
    Arch Gen Psychiatry; 2006 Dec; 63(12):1325-35. PubMed ID: 17146007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gender differences in cognition in schizophrenia.
    Perlick D; Mattis S; Stastny P; Teresi J
    Schizophr Res; 1992 Oct; 8(1):69-73. PubMed ID: 1358186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 39. [Psychopathologic and cognitive investigations in schizophrenia].
    Farkas M
    Orv Hetil; 2009 Mar; 150(9):423-9. PubMed ID: 19228571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
    Keefe RS; Fox KH; Harvey PD; Cucchiaro J; Siu C; Loebel A
    Schizophr Res; 2011 Feb; 125(2-3):161-8. PubMed ID: 21075600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.